Qatar
Tuberculosis profile
Population  2012 2.1 million
Estimates of TB burden * 2012 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) <0.01 (<0.01–<0.01) 0.17 (0.1–0.25)
Mortality (HIV+TB only) <0.01 (0–<0.01) 0.01 (0–0.06)
Prevalence  (includes HIV+TB) 1.2 (0.56–2.1) 60 (27–105)
Incidence  (includes HIV+TB) 0.84 (0.73–0.95) 41 (36–46)
Incidence (HIV+TB only) <0.01 (<0.01–<0.01) 0.04 (0–0.12)
Case detection, all forms (%) 87 (77–99)    
TB case notifications 2012        
New cases   (%) Retreatment cases (%)
Smear-positive 180 (25) Relapse 0  
Smear-negative 114 (16) Treatment after failure 0  
Smear-unknown / not done 217 (30) Treatment after default 0  
Extrapulmonary 217 (30) Other 0  
Other 0 (0)      
Total new 728   Total retreatment 0  
           
Other (history unknown) 0        
Total new and relapse 728   Total cases notified 728  
New cases Smear-positive Smear-negative/ unknown/
not done
Extrapulmonary
M:F ratio 8.0 4.4 3.7
Age < 15 2 4 4
Laboratories 2012
Smear (per 100 000 population) <0.1
Culture (per 5 million population) 2.4
Drug susceptibility testing (per 5 million population) 2.4
Is second-line drug susceptibility testing available? Yes, in country
Treatment success rate 2011 (%)        
New smear-positive and/or culture-positive 49   Is rifampicin used
throughout treatment for
new patients?
Yes
New smear-negative/extrapulmonary 100  
Retreatment    
TB/HIV 2012 Number (%)
TB patients with known HIV status 1 (<1)
HIV-positive TB patients 1 (100)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 1 (100)
HIV-positive TB patients on antiretroviral therapy (ART) 1 (100)
HIV-positive people screened for TB    
HIV-positive people provided with IPT    
Estimates of MDR-TB burden 2012*   New   Retreatment
% of TB cases with MDR-TB 1.2 (0.34–3.1) 0 (0–98)
MDR-TB cases among notified pulmonary
TB cases
6 (2–16) 0 (0–0)
Reported cases of MDR-TB 2012 New Retreatment Total
Cases tested for MDR-TB 10 (2%)   10
Laboratory-confirmed MDR-TB cases 2   2
Patients started on MDR-TB treatment     2
Financing TB control 2013
National TB programme budget (US$ millions)  
% Funded domestically  
% Funded internationally  
% Unfunded  
***
(Rate per 100 000 population per year)
Mortality graph
___ Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
___ Prevalence

(Rate per 100 000 population per year)
Incidence graph
__ Notifications Incidence
___
___ Incidence (HIV+TB only)

Treatment success rate (%)
tx success graph
__ New smear-positive and/or culture-positive
__ New smear-negative/extrapulmonary __
Retreatment

(Number of patients)
CPT ART graph
__ HIV-positive TB patients
__ on CPT __ on ART

Total budget (US$ millions)
Budget funding Graph
__ Funded domestically __ Funded internationally
__ Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 * Ranges represent uncertainty intervals Generated: 2014-04-23 Data: www.who.int/tb/data